Meibao Feng

Dr. Meibao Feng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in American Journal of Cancer Research
Verified
Journal Article
Closed access
MFMeibao Feng
Meibao Feng
XWXuesong Wu
Xuesong Wu
JZJing Zhang
Jing Zhang
PCPei Chen
Pei Chen
SQSenmi Qian
Senmi Qian
CCChengdong Chang
Chengdong Chang
Cisplatin is a widely used anti-cancer drug. Unfortunately, many cancers often develop resistance, which contributes to tumor recurrence and poorly prognosis. Growing knowledge has suggested the therapeutic potential of ferroptosis in cancer. Lipocalin2 (LCN2) is demonstrated to be a critical iron metabolic factor and implies in ferroptosis. Here, we aim to explore its role in chemotherapy resistance. The influence of LCN2 on colorectal cancer (CRC) cell chemoresistance and ferroptosis were evaluated by in vitro and in vivo approaches. The interaction between LCN2, NF-ĸB and ferroportin (FPN) was assessed by western blots, immunohistochemistry and dual luciferase reporter assays. Results showed that LCN2 was highly expressed in tumor regression grade 1 (TRG1) cases than that in TRG3 specimens. Loss of LCN2 contributed to resistance to cisplatin-induced ferroptosis. Mechanistically, loss of LCN2 inhibited cisplatin sensitivity and cisplatin-induced ferroptosis through elevating FPN expression which was regulated by NF-ĸB, subsequently reducing Fe2+ mediated Fenton reaction. Furthermore, FPN expression rate was much lower in TRG1 cases, and negative correlation between LCN2 and FPN expression was observed in clinical specimens. Collectively, low LCN2 expression enhances insensitivity of cisplatin to CRC cells via Fenton reaction mediated ferroptosis. LCN2/NF-ĸB/FPN pathway might be potentially utilized for chemoresistance strategy. LCN2 and FPN expression might be a promising biomarker of chemotherapy effect for CRC patients.

30 March 2022 in Research Square
Verified
Preprint
Open access
PDF file
SQSenmi Qian
Senmi Qian
MFMeibao Feng
Meibao Feng
Introduction: Primary collision tumors composed of two histologically distinct components are rare in the head and neck, its pathobiological features remain unclear. Case presentation: A man in his late 50s presented with paranesthesia pharynges and underwent upper endoscopy, followed by histopathological examination of biopsy specimens. He seems to have two tumors in the oropharynx with a size of 1.5*1.3cm, and an ulcer focus in the esophagus measuring about 1*0.8cm. Histopathological examination revealed a coexistence tumor of two components in the oropharynx, one was an adenocarcinoma with cribriform and solid growth pattern, with interstitial vitreous degeneration and central necrosis, the other was with a solid growth pattern, which was observed in both oropharynx and esophagus. The patient had a favorable outcome.Conclusion: Correct diagnosis can be challenging and is essential and beneficial for the prognosis of the patient.

9 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MFMeibao Feng
Meibao Feng
XWxuesong wu
xuesong wu
LJLi Jiang
Li Jiang
JHJinyan Huang
Jinyan Huang
JZJing Zhang
Jing Zhang
CCChengdong Chang
Chengdong Chang
Background: Colorectal cancers (CRCs) harboring the BRAFV600E (V600E) mutation exhibit aggressive clinical behavior and chemotherapy resistance, yet the underlying mechanisms remain poorly understood. Ferroptosis, which is driven by iron-dependent lipid peroxidation, has emerged as a potential therapeutic vulnerability. This study aimed to explore whether the NF-κB/Lipocalin 2 (LCN2) pathway modulates cisplatin sensitivity through Fenton-reaction-induced ferroptosis in BRAFV600E-overexpressing CRC cells. Methods: BRAF mutation status and the expression of LCN2, PTGS2, and cleaved caspase3 were examined in clinical CRC specimens by immunohistochemistry. The correlations between ferroptosis and apoptosis markers and 5-year survival rate were evaluated in TCGA datasets. CRC cells with LCN2 knockdown/knockout or BRAF/V600E/LCN2 overexpression were established to assess the proliferation, lipid metabolism, iron levels, and NF-κB/LCN2 signaling under cisplatin treatment. In vivo studies were employed with BALB/c xenograft models. Results: V600E-mutant clinical specimens exhibit significantly reduced expression of the ferroptosis marker PTGS2, and the iron metabolism regulators LCN2. Within a KRAS-mutant cellular model, V600E overexpression attenuated cisplatin-induced ferroptosis through suppression of the NF-κB/LCN2 signaling axis, leading to impairment of Fenton-reaction-mediated lipid peroxidation. Restoration of LCN2 expression re-sensitized V600E-overexpressing cells to cisplatin both in vitro and in vivo. Interestingly, inhibition of apoptosis contributes to the resistance of cisplatin induced ferroptosis in V600E overexpression cells, implying a crosstalk between ferroptosis and apoptosis within the therapeutic resistance. Conclusions: Our findings show that the NF-κB/LCN2 axis drives Fenton-reaction-induced ferroptosis to promote the vulnerability of V600E overexpression CRC cells within a KRAS-mutant background to cisplatin. LCN2 restoration partially overcomes V600E overexpression resistance both in vitro and in vivo, suggesting LCN2 as a promising therapeutic target. The crosstalk between ferroptosis and apoptosis may offer potential strategies to overcome chemotherapy resistance of this high-risk CRC subtype.